CST, 24799T, POLR1A (D6S6S) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying POLR1A. Validated for Western Blotting,Chromatin IP. Available in 2 sizes. Highly specific and rigorously validated in-house, POLR1A (D6S6S) Rabbit Monoclonal Antibody (CST #24799) is ready to ship. Product Usage Information For optimal ChIP results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 x 10 6 cells) per IP. This antibody has been validated using SimpleChIP ® Enzymatic Chromatin IP Kits. Western Blotting: 1:1000 Chromatin IP: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Chromatin IP Specificity / Sensitivity POLR1A (D6S6S) Rabbit Monoclonal Antibody recognizes endogenous levels of total POLR1A protein. Species Reactivity: Human, Mouse, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro36 of human POLR1A protein. Background RNA polymerase I (RNAPI) is a large multi-protein complex that functions as a DNA dependent, RNA polymerase, which is primarily responsible for the transcription of ribosomal RNA (rRNA) genes. The largest subunit, Rpa194, or POLR1A, along with selectivity factor 1 (SL1), and the transactivator protein upstream binding factor (UBF) make up the core transcriptional machinery of the RNAPI complex (1-3). The RNAPI complex is recruited specifically to rDNA promoters by SL1, which contains TBP and TAF proteins, to transcribe precursors to rRNA (2). These precursors are processed into 18S, 5.8S, and 28S mature rRNAs, which make up most of the ribosomal structure (1). Similar to the RNA polymerase II complex, there are other core components that are required for transcription of target genes such as the TFIIH complex and SPT6 (4, 5). Overexpression of nascent rRNA has been shown to be associated with poor prognosis in certain cancer types, and enlarged nucleoli are a hallmark of cellular proliferation and aggressive tumors (6-8). Oncogenes such as Myc, Ras, and PI3K can drive RNAPI-mediated rRNA transcription, making POLR1A a key therapeutic target (9). Indeed, specific targeting of RNAPI activity with a small molecule inhibitor can induce autophagy selectively in tumor cells while having minimal effects in normal cells (10). Additionally, mutations in POLR1A are associated with acrofacial dysostosis, Cincinnati type, a cranioskeletal malformation syndrome. Loss of function mutations result in disrupted ribosome biogenesis and p53-mediated cell death affecting skeletal precursor cells or the neural-crest (11). Alternate Names A190; AFDCIN; DKFZp586M0122; DNA-directed RNA polymerase I largest subunit; DNA-directed RNA polymerase I subunit A; DNA-directed RNA polymerase I subunit A1; DNA-directed RNA polymerase I subunit RPA1; FLJ21915; MGC87965; POLR1A; polymerase (RNA) I polypeptide A, 194kDa; polymerase (RNA) I subunit A; RNA polymerase I 194 kDa subunit; RNA polymerase I subunit A; RNA polymerase I subunit A1; RPA1; RPA190; RPA194; RPO1-4; RPO14 Specification REACTIVITY: H M Mk SENSITIVITY: Endogenous MW (kDa): 200 Source/Isotype: Rabbit IgG